EPA, FDA Agreements Aim To Clear Up Burdensome Regulatory Environment
This article was originally published in The Gray Sheet
Executive Summary
Complex, overlapping federal regulations potentially are blocking availability of innovative disinfectants for medical uses, speakers at a recent Food & Drug Law Institute meeting suggested
You may also be interested in...
Multi-Agency Nanotech Toxicity Initiative Funded At $105.9 Mil. In FY 2004
FDA will continue to monitor potential safety threats associated with some nanotechnology drug delivery devices, according to FDA Associate Commissioner for Science Norris Alderson, PhD
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.